Literature DB >> 23995597

Pharmacologic suppression of inflammation by a diphenyldifluoroketone, EF24, in a rat model of fixed-volume hemorrhage improves survival.

Vivek R Yadav1, Kaustuv Sahoo, Pamela R Roberts, Vibhudutta Awasthi.   

Abstract

An exaggerated release of proinflammatory cytokines and accompanying inflammation contributes to the development of multiple organ failure after hemorrhagic shock. Here, we tested the nuclear factor (NF) κ-light-chain-enhancer of activated B cell (NF-κB)-mediated transcriptional control of inflammatory pathways as a target in the management of hemorrhage-induced inflammation. We performed a study in a rat model of fixed-volume hemorrhage to investigate the anti-inflammatory effects of the diphenyldifluoroketone EF24 [3,5-bis(2-fluorobenzylidene)piperidin-4-one], an NF-κB inhibitor, in lung tissue. EF24 treatment (0.4 mg/kg) significantly prevented the upregulation of inflammatory biomarkers in rats subjected to 50% hemorrhage and preserved the pulmonary histology in hemorrhaged rats. The lung tissue from treated rats showed marked suppression of the hemorrhage-mediated induction of Toll-like receptor 4, phospho-p65 NF-κB, inducible nitric-oxide synthase, heme oxygenase-1, and cyclooxygenase-2 (COX-2). The hemorrhage-induced COX-2 activity was also significantly inhibited by the EF24 treatment. At the same time, EF24 induced nuclear factor (erythroid-derived 2)-like 2-mediated protective mechanisms against oxidative stress. EF24 also reduced hemorrhage-induced lung myeloperoxidase activity. The plasma levels of proinflammatory tumor necrosis factor-α, interleukin (IL)-6, IL-1α, and IL-1β were lower in EF24-treated rats than in untreated rats. Moreover, there was a significant reduction in the pulmonary expression of high-mobility group B1 protein. These biochemical effects were accompanied by a significant improvement in the survival of rats administered with EF24 as compared with the rats receiving vehicle control (P < 0.05). Overall, the results suggest that EF24 attenuates hemorrhage-induced inflammation and could serve as a salutary anti-inflammatory agent in resuscitation strategies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23995597      PMCID: PMC3807066          DOI: 10.1124/jpet.113.208009

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  56 in total

Review 1.  COX-2 inhibitors and cardiovascular risk. Inferences based on biology and clinical studies.

Authors:  Muhammad R Marwali; Jawahar L Mehta
Journal:  Thromb Haemost       Date:  2006-10       Impact factor: 5.249

2.  Glycyrrhizin prevents liver injury by inhibition of high-mobility group box 1 production by Kupffer cells after ischemia-reperfusion in rats.

Authors:  Masahito Ogiku; Hiroshi Kono; Michio Hara; Masato Tsuchiya; Hideki Fujii
Journal:  J Pharmacol Exp Ther       Date:  2011-07-07       Impact factor: 4.030

3.  An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements.

Authors:  K Itoh; T Chiba; S Takahashi; T Ishii; K Igarashi; Y Katoh; T Oyake; N Hayashi; K Satoh; I Hatayama; M Yamamoto; Y Nabeshima
Journal:  Biochem Biophys Res Commun       Date:  1997-07-18       Impact factor: 3.575

Review 4.  Signalling networks regulating cyclooxygenase-2.

Authors:  Christos Tsatsanis; Ariadne Androulidaki; Maria Venihaki; Andrew N Margioris
Journal:  Int J Biochem Cell Biol       Date:  2006-04-25       Impact factor: 5.085

Review 5.  Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS)

Authors:  R C Bone
Journal:  Ann Intern Med       Date:  1996-10-15       Impact factor: 25.391

6.  Toll-like receptor 4 regulates heme oxygenase-1 expression after hemorrhagic shock induced acute lung injury in mice: requirement of p38 mitogen-activated protein kinase activation.

Authors:  Chang Chen; Yanlin Wang; Zongze Zhang; Chengyao Wang; Mian Peng
Journal:  Shock       Date:  2009-05       Impact factor: 3.454

Review 7.  Nrf2 signaling in coordinated activation of antioxidant gene expression.

Authors:  Anil K Jaiswal
Journal:  Free Radic Biol Med       Date:  2004-05-15       Impact factor: 7.376

Review 8.  Hemorrhagic shock.

Authors:  A B Peitzman; T R Billiar; B G Harbrecht; E Kelly; A O Udekwu; R L Simmons
Journal:  Curr Probl Surg       Date:  1995-11       Impact factor: 1.909

9.  Cerebral oxygen delivery by liposome-encapsulated hemoglobin: a positron-emission tomographic evaluation in a rat model of hemorrhagic shock.

Authors:  Vibhudutta Awasthi; Seong-Hwan Yee; Paul Jerabek; Beth Goins; William T Phillips
Journal:  J Appl Physiol (1985)       Date:  2007-07

Review 10.  ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis.

Authors:  Benoît D'Autréaux; Michel B Toledano
Journal:  Nat Rev Mol Cell Biol       Date:  2007-10       Impact factor: 94.444

View more
  12 in total

1.  Anti-inflammatory mediators ST2 and SIGIRR are induced by diphenyldifluoroketone EF24 in lipopolysaccharide-stimulated dendritic cells.

Authors:  Vibhudutta Awasthi; Prachi Vilekar; Geeta Rao; Shanjana Awasthi
Journal:  Immunobiology       Date:  2019-11-29       Impact factor: 3.144

2.  Nanovesicular liposome-encapsulated hemoglobin (LEH) prevents multi-organ injuries in a rat model of hemorrhagic shock.

Authors:  Vivek R Yadav; Geeta Rao; Hailey Houson; Andria Hedrick; Shanjana Awasthi; Pamela R Roberts; Vibhudutta Awasthi
Journal:  Eur J Pharm Sci       Date:  2016-08-05       Impact factor: 4.384

3.  Hemorrhage-induced interleukin-1 receptor pathway in lung is suppressed by 3,5-bis(2-fluorobenzylidene)-4-piperidone in a rat model of hypovolemic shock.

Authors:  Vivek R Yadav; Prachi Vilekar; Shanjana Awasthi; Vibhudutta Awasthi
Journal:  Artif Organs       Date:  2014-04-22       Impact factor: 3.094

4.  Hemorrhagic shock-induced cerebral bioenergetic imbalance is corrected by pharmacologic treatment with EF24 in a rat model.

Authors:  Geeta Rao; Jun Xie; Andria Hedrick; Vibhudutta Awasthi
Journal:  Neuropharmacology       Date:  2015-07-29       Impact factor: 5.250

5.  Remediation of hemorrhagic shock-induced intestinal barrier dysfunction by treatment with diphenyldihaloketones EF24 and CLEFMA.

Authors:  Vivek R Yadav; Alamdar Hussain; Kaustuv Sahoo; Vibhudutta Awasthi
Journal:  J Pharmacol Exp Ther       Date:  2014-09-09       Impact factor: 4.030

6.  The curcuminoid, EF-24, reduces cisplatin-mediated reactive oxygen species in zebrafish inner ear auditory and vestibular tissues.

Authors:  Jerry D Monroe; Matthew H Millay; Blaine G Patty; Michael E Smith
Journal:  J Clin Neurosci       Date:  2018-09-20       Impact factor: 1.961

7.  Induction of gut proteasome activity in hemorrhagic shock and its recovery by treatment with diphenyldihaloketones CLEFMA and EF24.

Authors:  Geeta Rao; Hailey Houson; Gregory Nkepang; Hooman Yari; Chengwen Teng; Vibhudutta Awasthi
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-05-10       Impact factor: 4.052

8.  The salutary effects of diphenyldifluoroketone EF24 in liver of a rat hemorrhagic shock model.

Authors:  Vivek R Yadav; Alamdar Hussain; Jun Xie; Stanley Kosanke; Vibhudutta Awasthi
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2015-02-03       Impact factor: 2.953

9.  Autophagy and apoptosis in hepatocellular carcinoma induced by EF25-(GSH)2: a novel curcumin analog.

Authors:  Tao Zhou; Lili Ye; Yu Bai; Aiming Sun; Bryan Cox; Dahai Liu; Yong Li; Dennis Liotta; James P Snyder; Haian Fu; Bei Huang
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

10.  Diphenyldifluoroketone EF24 Suppresses Pro-inflammatory Interleukin-1 receptor 1 and Toll-like Receptor 4 in lipopolysaccharide-stimulated dendritic cells.

Authors:  Prachi Vilekar; Geeta Rao; Shanjana Awasthi; Vibhudutta Awasthi
Journal:  J Inflamm (Lond)       Date:  2015-09-23       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.